Consejo Superior De Investigaciones Cientificas

Fundacio Institut De Recerca De L'hospital De La Santa Creu I Sant Pau

Instituto Catalan De Ciencias Cardiovasculares (iccc)

Fundació Institut De Recerca De L'hospital De La Santa Creu I Saint Pau

Gendiag, S.l.

Lina Badimon Maestro

Teresa Padró Capmany

Judit Cubedo Ràfols

Gemma Vilahur Garcia

Concepción Vicenta Llorente Cortés

The invention relates to methods for the diagnosis of ischemia or ischemic tissue damage, methods for predicting the progression of ischemia in a patient having suffered an ischemic event, for determining the prognosis of a patient having suffered an ischemic event and for determining the risk that a patient suffering from stable coronary disease suffers a recurrent ischemic event based on the detection of the levels of glycosylated Apo J. The invention relates as well to a method for the determination of glycosylated Apo J in a sample.

Methods and kits for the diagnosis and risk stratification of patients with ischemia

The present invention relates to pharmaceutical compositions comprising a compound selected from the group consisting of: a) a polypeptide of SEQ ID NO:1, b) a functionally equivalent variant of the polypeptide according to a), c) a polynucleotide encoding a) or b), d) a vector comprising a polynucleotide according to c), e) a cell capable of secreting into the medium a polypeptide according to a) or b), and f) a nanoparticle comprising the polypeptide according to a) or b) and a pharmaceutically acceptable excipient. The invention also relates to the use of said compounds or pharmaceutical compositions for treatment and/or prevention of ischemia injury or ischemia/reperfusion injury in a subject.

Prevention and/or treatment of ischemia or ischemia/reperfusion injury

The invention relates to novel molecules that can modulate one of the mechanisms leading to the massive deposition of cholesterol in the cardiomyocytes and/or in the smooth muscle cells of the vascular wall, during acute myocardial infarction or other clinical situations involving ischaemia. The invention also shows that the blockage of LRP1 by means of certain agents, including a recombinant expression vector, an RNAi, an antibody, a siRNA etc., prevents the overaccumulation of esterified cholesterol in the cardiomyocytes and/or in the smooth muscle cells of the vascular wall exposed to ischaemia. The invention also relates to the use of said molecules in the treatment and/or prevention of the changes in the metabolism of calcium and cardiac remodeling associated with ischaemia.

LRP1 as key receptor for the transfer of sterified cholesterol from very-low-density lipoproteins (VLDL) to ischaemic cardiac muscle

Growing community of inventors

Barcelona, Spain

Lina Badimon Maestro